Aprea Therapeutics Reports Second Unconfirmed Partial Response for WEE1 Inhibitor APR-1051 in Phase 1 Study

summarizeSummary

Aprea Therapeutics reported a second unconfirmed partial response for its WEE1 inhibitor, APR-1051, in a Phase 1 study, showing significant tumor shrinkage and biomarker reduction with good tolerability.

check_boxKey Events

• Second Unconfirmed Partial Response Achieved

  A patient with advanced endometrial cancer in the Phase 1 ACESOT-1051 study achieved a second unconfirmed partial response (uPR) at the 220 mg dose level.

• Significant Tumor Shrinkage and Biomarker Reduction

  The responding patient showed a 50% reduction in target lesion measurements and an 87% decline in the CA-125 tumor biomarker, from 362 U/mL to 47 U/mL.

• Favorable Safety Profile

  The patient experienced only Grade 1 treatment-emergent adverse events and continues treatment, supporting a potentially improved therapeutic index for APR-1051.

• Genomically Guided Patient Selection

  Both patients with uPRs to date harbored PPP2R1A mutations, reinforcing the mechanistic thesis of targeting WEE1 for this specific patient population.

auto_awesomeAnalysis

Aprea Therapeutics announced a second unconfirmed partial response (uPR) in its Phase 1 ACESOT-1051 study for its WEE1 inhibitor, APR-1051. This positive clinical update is highly significant for the micro-cap biopharmaceutical company, especially following a recent Nasdaq deficiency letter and a dilutive private placement. The observed 50% tumor shrinkage and substantial 87% reduction in the CA-125 biomarker, coupled with a favorable safety profile (only Grade 1 adverse events), provide further evidence of APR-1051's biological activity and therapeutic potential in advanced endometrial cancer patients with PPP2R1A mutations. This reinforces the company's development strategy and could help improve investor sentiment and address concerns about its financial and compliance status. Investors should monitor the confirmation of these responses and the further update expected in Q2 2026.